SG11201912172YA - Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva - Google Patents

Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Info

Publication number
SG11201912172YA
SG11201912172YA SG11201912172YA SG11201912172YA SG11201912172YA SG 11201912172Y A SG11201912172Y A SG 11201912172YA SG 11201912172Y A SG11201912172Y A SG 11201912172YA SG 11201912172Y A SG11201912172Y A SG 11201912172YA SG 11201912172Y A SG11201912172Y A SG 11201912172YA
Authority
SG
Singapore
Prior art keywords
melatonin
saliva
renders
soluble
acidifying agent
Prior art date
Application number
SG11201912172YA
Other languages
English (en)
Inventor
Syed M Shah
Daniel Hassan
Fred Hassan
Patrick Corsino
Original Assignee
Physicians Seal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal Llc filed Critical Physicians Seal Llc
Publication of SG11201912172YA publication Critical patent/SG11201912172YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201912172YA 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva SG11201912172YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (1)

Publication Number Publication Date
SG11201912172YA true SG11201912172YA (en) 2020-01-30

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912172YA SG11201912172YA (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200018652A (cg-RX-API-DMAC7.html)
CN (1) CN110913853A (cg-RX-API-DMAC7.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC7.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC7.html)
CA (1) CA3067822C (cg-RX-API-DMAC7.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019015733A (cg-RX-API-DMAC7.html)
RU (1) RU2020101742A (cg-RX-API-DMAC7.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC7.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2880618T3 (es) 2015-03-02 2021-11-25 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Also Published As

Publication number Publication date
WO2018236678A1 (en) 2018-12-27
US20200268886A1 (en) 2020-08-27
KR20200018652A (ko) 2020-02-19
US11224658B2 (en) 2022-01-18
RU2020101742A (ru) 2021-07-20
AU2018289284A1 (en) 2020-01-16
US20180360967A1 (en) 2018-12-20
US10960075B2 (en) 2021-03-30
US11224657B2 (en) 2022-01-18
CN110913853A (zh) 2020-03-24
US20200069803A1 (en) 2020-03-05
US20200268887A1 (en) 2020-08-27
BR122021012549B1 (pt) 2022-02-22
ES2979335T3 (es) 2024-09-25
BR122021012549B8 (pt) 2022-10-25
JP7297685B2 (ja) 2023-06-26
CA3067822A1 (en) 2018-12-27
BR112019027286A2 (pt) 2020-07-21
EP3641759B1 (en) 2024-04-03
BR112019027286B1 (pt) 2022-02-22
US10500280B2 (en) 2019-12-10
EP3641759A4 (en) 2021-03-24
JP2020524162A (ja) 2020-08-13
CA3067822C (en) 2022-08-30
MX2019015733A (es) 2020-02-20
EP3641759A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
DK3720496T3 (en) Solid oral nicotine formulation
IL252596A0 (en) History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL263295A (en) Venturi effect-preventing vehicle delivery in electronic inhalers
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
IL250752A0 (en) Device with compounds for conduction to lungs, oral mucosa and brain
HUE053332T2 (hu) Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
PL3481846T3 (pl) 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
WO2014165226A3 (en) Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
DK3244878T3 (da) Faste orale sammensætningsformer
IL257652A (en) A drug formulation based on particles containing a polysaccharide-vitamin conjugate
PL3240550T3 (pl) Kombinacja glikozaminoglikanów i środka zobojętniającego kwas i ich kompozycje
EP3229824A4 (en) Oral octreotide administered in combination with other therapeutic agents
IL250267A0 (en) History of indolizine, their preparation and pharmaceutical preparations containing them
PL3232780T3 (pl) Kompozycje adiuwantowe zawierające wodny elektrolit, kompozycje zawierające składnik czynny i ich zastosowanie
SMT202200386T1 (it) Composizioni appetibili contenenti fenilbutirrato sodico e loro usi
SMT202500321T1 (it) Composizioni liofilizzate ad area superficiale elevata comprendenti arsenico per la somministrazione orale a pazienti
EP3641759A4 (en) ORAL SOLUBLE MELATONIN FORMULATION WITH ACID AGENT FOR THE SOLUBILITY OF MELATONIN IN SALIVA
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
SG10202008700VA (en) α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
IL262204A (en) Granular formulation for oral administration
EP3508193A4 (en) ORAL COMPOSITION AND MOUTHPLATE DISPERSING AGENT
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
IL271673A (en) Preparations containing drugs with increased solubility
IL274868A (en) History of imidazopyridine and their use as medicine